The rapamycin trial in dogs, and why it will not answer the question until 2029
TRIAD is randomised, double-blind and placebo-controlled, with lifespan as its primary endpoint. That design is the reason it is slow, and the reason it will be worth reading when it reports.
Editorial placeholder for an article about the TRIAD rapamycin trial
One claim in this article is preliminary or not demonstrated. It is marked where it appears, with what it does not establish.
If you want to know whether a drug extends life, there is only one way to find out, and it is slow: give it to a randomly assigned group, give an identical-looking placebo to another, make sure nobody involved knows which is which, and then wait.
TRIAD is doing that in companion dogs, in their own homes, with their own veterinarians. It is the most methodologically serious thing happening in canine longevity, and its timeline is a feature rather than a failing.
TRIAD is a randomised, double-blind, placebo-controlled trial targeting 580 dogs aged seven and over. Dogs receive rapamycin or placebo for one year, followed by two years of observation.
The primary endpoint is lifespan. Secondary endpoints include measures of physiological health and age-related disease markers such as arthritis and kidney function.
Why it takes this long
A lifespan endpoint cannot be hurried. You cannot measure how long dogs live without the dogs living, and you cannot substitute a marker for the outcome without assuming the very thing the trial is meant to test.
This is exactly the discipline that distinguishes it from the supplement market, where a product can be formulated, marketed and sold in less time than it takes this trial to enrol.
The trial is slated to conclude in November 2029. Over 180 dogs had enrolled toward the 580-dog target at the time of the most recent reporting.
Funding has not been continuous: a lapse in 2024 was followed by a five-year, $7 million National Institute on Aging grant in 2025, of which only the first year had been received at the time of reporting.
You cannot measure how long dogs live without the dogs living. Everything faster than this is measuring something else.
What is and is not known today
Rapamycin extends lifespan in mice. That is well established, and it is the reason anyone is testing it in dogs. It is not a reason to give it to a dog, because species differ and the history of ageing research is substantially a history of mouse results that did not transfer.
TIMOMAX's position on this is simple: this is the trial to watch, and until it reports there is no honest way to tell an owner that rapamycin will help their dog.
No efficacy results exist yet. Earlier Dog Aging Project work found rapamycin well tolerated with a limited side-effect profile, which is a safety observation and not evidence of benefit.
What this does not establish. Tolerability tells you the drug can be given, not that it does anything. Anyone offering rapamycin to a healthy dog for longevity today is doing so ahead of the evidence this trial exists to produce.
The register, in one place. Each claim is graded individually because a single article legitimately contains settled consensus and open questions in the same paragraph — the citations and the stated limits sit with each claim above.
TRIAD is a randomised, double-blind, placebo-controlled trial targeting 580 dogs aged seven and over. Dogs receive rapamycin or placebo for one year, followed by two years of observation.
The primary endpoint is lifespan. Secondary endpoints include measures of physiological health and age-related disease markers such as arthritis and kidney function.
The trial is slated to conclude in November 2029. Over 180 dogs had enrolled toward the 580-dog target at the time of the most recent reporting.
No efficacy results exist yet. Earlier Dog Aging Project work found rapamycin well tolerated with a limited side-effect profile, which is a safety observation and not evidence of benefit.
Funding has not been continuous: a lapse in 2024 was followed by a five-year, $7 million National Institute on Aging grant in 2025, of which only the first year had been received at the time of reporting.
TIMOMAX did not conduct this research. This article summarises the work below; the principal source is American Veterinary Medical Association.
- 1Principal source$7M grant rescues dog study investigating rapamycin for canine agingAmerican Veterinary Medical Association·Veterinary institution
- 2TRIAD — Test of Rapamycin in Aging DogsDog Aging Project·Trial registry
- 3Dog Aging Project Test of Rapamycin in Aging Dogs (TRIAD)Cummings School of Veterinary Medicine, Tufts University·Veterinary institution
This is general education, not advice about your animal. TIMOMAX is not a veterinarian and cannot examine anything. If something has changed about your animal, that is a question for a veterinary practice — and most will answer it on the phone.